Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Schemionek M, Elling C, Steidl U, Bäumer N, Hamilton A, Spieker T, Göthert JR, Stehling M, Wagers A, Huettner CS, Tenen DG, Tickenbrock L, Berdel WE, Serve H, Holyoake TL, Müller-Tidow C, Koschmieder S.

Blood. 2010 Apr 22;115(16):3185-95. doi: 10.1182/blood-2009-04-215376. Epub 2010 Jan 6.

2.

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Koschmieder S, Göttgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, Dayaram T, Geary K, Green AR, Tenen DG, Huettner CS.

Blood. 2005 Jan 1;105(1):324-34. Epub 2004 Aug 26.

3.

Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia.

Jiang X, Stuible M, Chalandon Y, Li A, Chan WY, Eisterer W, Krystal G, Eaves A, Eaves C.

Blood. 2003 Oct 15;102(8):2976-84. Epub 2003 Jun 26.

5.

[Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].

Akhlynina TV, Gerasimova LP, Sarkisian GP, Borovkova TV, Dukhovenskaia EA, Manakova TE, Naĭdenova NM, Timofeev AM, Grineva NI.

Tsitologiia. 2007;49(10):889-900. Russian.

PMID:
18074781
6.

Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.

Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ.

Oncogene. 2001 May 10;20(21):2636-46.

7.

Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.

Kometani K, Aoki M, Kawamata S, Shinozuka Y, Era T, Taniwaki M, Hattori M, Minato N.

Cancer Res. 2006 Oct 15;66(20):9967-76.

8.

Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.

Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G, Hoffman R.

Blood. 1993 Feb 1;81(3):801-7.

9.

Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.

Miyazaki K, Yamasaki N, Oda H, Kuwata T, Kanno Y, Miyazaki M, Komeno Y, Kitaura J, Honda Z, Warming S, Jenkins NA, Copeland NG, Kitamura T, Nakamura T, Honda H.

Blood. 2009 May 7;113(19):4702-10. doi: 10.1182/blood-2007-05-088724. Epub 2009 Feb 20.

10.

Disease progression in a murine model of bcr/abl leukemogenesis.

van Etten RA.

Leuk Lymphoma. 1993;11 Suppl 1:239-42. Review.

PMID:
8251903
11.

Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.

Veena P, Cornetta K, Davidson A, Agüero B, McMahel J, Traycoff CM, Srour EF.

Bone Marrow Transplant. 1997 Jun;19(12):1213-21.

12.

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D, Williams IR, Akashi K, Gilliland DG.

Cancer Cell. 2004 Dec;6(6):587-96.

13.

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.

Warmuth M, Danhauser-Riedl S, Hallek M.

Ann Hematol. 1999 Feb;78(2):49-64. Review.

PMID:
10089019
14.

Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.

Gishizky ML, Johnson-White J, Witte ON.

Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3755-9.

15.

Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy.

Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS, Kutok JL, Gilliland DG, Krauter J, Tenen DG.

Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6338-43. Epub 2006 Apr 10.

16.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ.

Blood. 2003 Jun 15;101(12):4701-7. Epub 2003 Feb 6.

17.
18.

Chronic myelogenous leukemia: molecular and cellular aspects.

Pasternak G, Hochhaus A, Schultheis B, Hehlmann R.

J Cancer Res Clin Oncol. 1998;124(12):643-60. Review.

PMID:
9879825
19.
20.

Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.

Zheng X, Oancea C, Henschler R, Moore MA, Ruthardt M.

PLoS One. 2009 Oct 30;4(10):e7661. doi: 10.1371/journal.pone.0007661.

Items per page

Supplemental Content

Write to the Help Desk